← All indications
Lung Neoplasms
Tumors or cancer of the LUNG.
Subtype terms (8)
More specific conditions that are subtypes of Lung Neoplasms in the MeSH hierarchy.
- Adenocarcinoma of Lung
97 drugs (47 approved, 50 experimental)
- Bronchial Neoplasms
21 drugs (11 approved, 10 experimental)
- Carcinoma, Bronchogenic
24 drugs (15 approved, 9 experimental)
- Mesothelioma, Malignant
131 drugs (66 approved, 65 experimental)
- Multiple Pulmonary Nodules
7 drugs (4 approved, 3 experimental)
- Pancoast Syndrome
3 drugs approved
- Pulmonary Blastoma
- Pulmonary Sclerosing Hemangioma
Drugs by status
Approved for this indication (7)
Phase 4 trials (55)
- alectinib
- morphine
- beta carotene
- dronabinol
- budesonide
- levobupivacaine
- docetaxel
- iodixanol
- fludeoxyglucose f-18
- urea
- nivolumab
- sevoflurane
- lidocaine
- porfimer
- lapatinib
- zoledronic acid
- ropivacaine
- erlotinib
- cisplatin
- ketamine
- ibuprofen
- fentanyl
- remifentanil
- acetylcysteine
- propofol
- Filgrastim
- thalidomide
- ibandronate
- dexmedetomidine
- mirtazapine
- +25 more
Phase 3 trials (148)
- tislelizumab
- vandetanib
- pralsetinib
- gefitinib
- epoetin
- lanreotide
- talabostat
- anamorelin
- melatonin
- azd-4547
- isotretinoin
- amiodarone
- hs-20093
- escitalopram
- oxaliplatin
- cellulose
- lemon
- 99mtc ecdg
- ganitumab
- almonertinib
- pembrolizumab
- shr-a1811
- strontium-89
- leucovorin
- pacritinib
- gdc-6036
- 99mtc-3prgd2
- vitamin e
- levofloxacin
- HPV16-E7-T512
- +118 more
Phase 2 trials (462)
- keyhole limpet hemocyanin
- lazertinib
- itraconazole
- vitespen
- pasireotide
- fluoromisonidazole
- Activated CIK with CD3-MUC1
- blu-945
- blu-701
- poziotinib
- t3011
- motesanib
- talimogene laherparepvec
- htl0039732
- Acridine Carboxamide
- palifermin
- shr-1701
- ter-2013
- autologous natural killer cells
- ibrutinib
- pr-104
- treosulfan
- selenomethionine se-75
- azd-5672
- sorafenib
- ny-eso-1 peptides
- ide397
- rucaparib
- plinabulin
- foretinib
- +432 more
Phase 1 trials (272)
- tegavivint
- allogeneic k562 tumor cells
- BL-B01D1
- gm-ct-01
- 111in-etn029
- vedolizumab
- rgx-104
- bbo-11818
- mnpr-101-dfo*-89zr
- autologous microbiome
- cea-loaded dendritic cells
- 131i-lipiodol
- nxp900
- MCLA-129
- pf-06940434
- kb707
- klh conjugates of gd2l, gd3l, globo h, fucosyl gm1
- tbi-1301
- ido peptide
- rgd-k5
- emd 521873
- n-propionylated polysialic acid
- myoinositol
- bi 765049
- vaccine 1650-g
- ganetespib
- poly-iclc
- bbi-355
- 18f-fmau
- azd1236
- +242 more
Other trials (48)
- fondaparinux sodium
- iohexol
- amino acids
- deuterated phenanthrene
- F 18-fluoroazomycin arabinoside
- cu 64 m5a
- maitake mushroom extract
- [68ga]ga-nota-epcd6
- tc-99m dtpa
- arginine
- tobacco
- [68ga]ga-nota-t4
- [18f]f-resca-epcd6
- calcipotriene
- fowlpox-sargramostim
- sanguisorba officinalis l.
- glse
- armodafinil
- gt201
- hyaluronic acid
- qishen
- ga-nota-rt4
- 18f-wl12
- iron sucrose
- [18f]f-resca-t4
- magnesium oxide
- nkt cells
- cu64 trastuzumab
- zinc sulfate
- sufentanil
- +18 more
Organizations
Organization Involved with Phase 4 Indications (78)
- National Cancer Institute (NCI)
- Eli Lilly
- Amgen
- Shantou University
- Capital Medical University
- Hangzhou Normal University
- University of Montreal
- Roche
- Peter MacCallum Cancer Centre
- Radboud University
- Beijing Zheng Ju Medical Technology Co., Ltd.
- Bristol-Myers Squibb
- Taipei Veteran General hospital
- Chinese Academy of Medical Sciences
- Zhejiang University
- Pfizer
- Johnson and Johnson
- Hacettepe University
- Celgene
- China Academy of Chinese Medical Sciences
- Catalysis SL
- Jiao Tong University
- Betta Pharmaceuticals Co.,Ltd.
- Wenzhou Medical University
- Sankt Lukas Hospice
- Guangzhou Pharmaceucal Company Limited
- AstraZeneca
- People's Liberation Army of China
- Luye Pharma
- Janssen Pharmaceutica NV
- +48 more
Organization Involved with Phase 3 Indications (361)
- Biothera
- SK Chemicals
- LabCorp
- Government of Japan
- Abbott
- Agennix
- Federation of Italian Cooperative Oncology Groups
- University of Groningen
- University of Bari
- Fatebenefratelli Hospital
- Seoul National University
- University of Limoges
- Immunotec Inc.
- Memorial Sloan-Kettering Cancer Center
- National Cancer Center, Korea
- Japan Multinational Trial Organization
- IQVIA
- Medical Research Council
- Fondazione Giovanni Pascale
- Agouron
- Thomas Jefferson University
- Hospital Avicenne
- University of British Columbia
- Martha-Maria Krankenhaus Halle-Dölau gGmbH
- Gansu Provincial Hospital
- Zhejiang Betapharma Inc.
- EpicentRx, Inc.
- Gruppo Oncologico Italiano di Ricerca Clinica
- ICON
- European Organisation for Research and Treatment of Cancer
- +331 more
Organization Involved with Phase 2 Indications (603)
- Teva
- Ospedale Santa Croce-Carle Cuneo
- University of Arizona
- Burzynski Research Institute
- Gyeongsang University
- Johannes Gutenburg University
- Benxi City hospital of Chinese medicine
- Advenchen Laboratories, LLC
- Vertex
- ASL TO4, Chivasso
- B.P. Poddar Hospital and Medical Research Ltd.
- Drammen sykehus
- Personal Genome Diagnostics (PGDx)
- Clinica Universidad de Navarra
- Chittaranjan National Cancer Institute
- Showa University
- Adaptimmune
- RWTH Aachen University
- Veeda Clinical Research
- Clearview Cancer Institute
- NuRx Pharmaceuticals, Inc.
- Nanchang University
- Wuhan University
- CureVac AG
- Immunomedics
- Telik
- Regione Lombardia
- WindMIL Therapeutics
- University of Nebraska
- Herbert Irving Comprehensive Cancer Center
- +573 more
Organization Involved with Phase 1 Indications (117)
- Shenzhen University
- Virginia Oncology Associates
- Neurocrine Biosciences
- Asbestos Diseases Research Foundation
- Kyowa Kirin
- Comprehensive Cancer Centers of Nevada
- Biogen
- University of Manchester
- Golden Biotechnology Corp.
- Impact Therapeutics, Inc.
- Chugai
- Askelios Klinik München Gauting
- PharmaNet
- Philogen S.p.A.
- Morphotek
- Compugen
- Theraclion
- Guangzhou Yiyang Biological Technology Co., Ltd.
- NewVac LLC
- Heatlhcare Pharmaceuticals
- Nilogen Oncosystems
- Vasgene Therapeutics, Inc
- Xinxiang Medical University
- Singapore Clinical Research Institute
- Checkmate Pharmaceuticals
- Innovive Pharmaceuticals
- Willamette Valley Cancer Institute
- NHS Lothian
- Xynomic Pharmaceuticals, Inc.
- Shin Kong Wu Ho-Su Memorial Hospital
- +87 more
Organization Involved with Other Experimental Indications (18)
- Karolinska Institute
- Surgery Bitenc
- Yorkshire Cancer Research
- Korea Institute of Oriental Medicine
- University of York
- Qidong Gaitianli Medicines Co., Ltd
- Akorn, Inc.
- Shandong University of Traditional Chinese Medicine
- Bionical Emas
- Deakin University
- Hubei Mon Yan Pharmaceutical Co., Ltd
- Barwon Health
- Beijing Yijiayi Medicine Techonoloy Co., Ltd.
- Stemirna Therapeutics
- Sacro Cuore Don Calabria General Hospital
- Shandong Provincial Hospital
- Centre Leon Berard
- Personal Improvement Computer Systems